兴银研究精选股票A（008537）成立日期2020年7月29日，最新规模4472.5万。今年以来收益24.07%， 同类排名2354/4220；近一年收益54.23%，同类排名1673/3824；成立以来收益8.1%。 9月26日，华恒生物涨5.17%，截至发稿，报34.60元/股，成交1.81亿元，换手率2.15%，总市值86.54亿 元。 资料显示，安徽华恒生物科技股份有限公司位于安徽省合肥市高新区长安路197号，成立日期2005年4月 13日，上市日期2021年4月22日，公司主营业务涉及氨基酸及其衍生物产品研发、生产、销售。主营业 务收入构成为：氨基酸系列70.96%，其他(补充)20.96%，维生素系列5.34%，其他产品2.74%。 从基金十大重仓股角度 数据显示，兴银基金旗下1只基金重仓华恒生物。兴银研究精选股票A（008537）二季度持有股数4.11万 股，占基金净值比例为2.42%，位居第七大重仓股。根据测算，今日浮盈赚取约6.99万元。 责任编辑：小浪快报 兴银研究精选股票A（008537）基金经理为乔华国。 截至发稿，乔华国累计任职时间1年323天，现任基金资产总规模1.18亿元，任职期 ...

Group 1 - The core point of the article is that Lichen Industrial (丽臣实业) has confirmed the annual production capacity of its Shanghai Aowei factory to be approximately 250,000 tons, focusing on the production of various green surfactant products [1] - The main products produced at the Shanghai Aowei factory include AES, K12, LAS, amino acid series, and APG [1]

Core Insights - The report highlights the significant increase in CFO salaries within A-share listed companies, with a total compensation of 4.27 billion yuan and an average salary of 814,800 yuan for 2024 [1][2] - Despite a 74.42% decline in stock price, CFO Fan Yi of Huaheng Biological saw a salary increase of 48.18%, raising concerns about the disconnect between executive compensation and company performance [1][2] Summary by Sections CFO Salary Overview - The total salary for CFOs in A-share listed companies reached 4.27 billion yuan in 2024, with an average salary of 814,800 yuan [1] - Huaheng Biological's CFO, Fan Yi, received a salary of 1.62 million yuan, an increase of 526,700 yuan or 48.18% from the previous year [1][3] Company Performance - Huaheng Biological reported a total revenue increase of 12.37% to 2.178 billion yuan, but its net profit dropped by 57.80% to 190 million yuan [1] - The company's stock price fell by 74.42%, indicating a poor market performance despite revenue growth [1][2] Executive Background - Fan Yi has been with Huaheng Biological since January 2016, holding multiple roles including CFO and board secretary, and has prior experience in finance and mergers at BASF Greater China [2]